Company: Regeneron Pharmaceuticals Inc.
Headquarters: Tarrytown, New York, USA
Founded: 1988
NASDAQ: REGN
Market Cap (2026): ~$95 billion USD
Employees: ~14,000
Website: [regeneron.com](https://www.regeneron.com)
Overview
Mermaid diagram (expand to render)
Regeneron Pharmaceuticals is one of the world's largest biotechnology companies, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron has built a reputation for innovation in antibody therapeutics, genomics, and neuroscience research. The company operates a fully integrated biopharmaceutical business spanning discovery, development, manufacturing, and commercial operations["@regeneron"].
Regeneron's neuroscience pipeline represents a significant strategic focus, with programs targeting Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and other CNS disorders. The company's VelociSuite technology platform enables rapid identification and development of therapeutic antibodies, positioning it competitively in the neurodegeneration space["@regenerona"].
The company's success story centers on its scientific leadership in antibody discovery and its ability to translate basic research into marketed products. With annual revenues exceeding $14 billion and a robust R&D budget of $3.2 billion, Regeneron has the financial resources to pursue ambitious neuroscience programs["@regeneron"].
Corporate History
Founding and Early Years (1988-2000)
Regeneron was founded in 1988 by Dr. Leonard Schleifer (CEO) and Dr. George Yancopoulos (President & Chief Scientific Officer) with a focus on cytokine biology and receptor-Fc fusion proteins. The company's early research focused on understanding the neurotrophin family of growth factors and their receptors.
The name "Regeneron" combines "regenerate" and "neuron," reflecting the company's early vision of developing therapeutics that could regenerate neurons damaged by disease or injury. This vision, while not yet realized in the clinic, continues to inform the company's neuroscience research programs.
The 2000s saw Regeneron develop its proprietary technology platforms:
- VelociImmune (2002): A mouse platform capable of producing fully human monoclonal antibodies, revolutionizing antibody drug discovery
- VelociGene (2005): Rapid gene targeting in mammalian cells
- VelociMouse (2008): Complete mice strains from targeted embryonic stem cells
These platforms enabled Regeneron to build a robust pipeline of antibody therapeutics.
Breakthrough Decade (2010-Present)
The 2010s brought transformative success:
- Eylea (2011): VEGF inhibitor for age-related macular degeneration, becoming one of the world's best-selling drugs
- Dupixent (2017): IL-4R antibody for atopic dermatitis, asthma, and other Type 2 inflammatory diseases
- Libtayo (2018): PD-1 inhibitor for cutaneous squamous cell carcinoma
The company's neuroscience ambitions accelerated in the mid-2020s through a strategic partnership with Alnylam Pharmaceuticals, gaining access to RNAi technology for CNS gene silencing[@alnylam].
Pipeline / Products (Updated Q1 2026)
Neuroscience Programs
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| Efanetig (EYESCARE) | [Amyloid-beta](/proteins/amyloid-beta) antibody | Alzheimer's Disease | Phase 3 | Active |
| ALN-5288 | siRNA (MAPT gene silencing) | Alzheimer's Disease (Tau) | Phase 1 | Active |
| ALN-HTT02 | siRNA (HTT gene silencing) | Huntington's Disease | Phase 1 | Active |
| ALN-SNCA | siRNA (SNCA gene silencing) | [Parkinson's Disease](/diseases/parkinsons-disease) | Phase 1 | Active |
| ALN-SOD1 | siRNA (SOD1 gene silencing) | [ALS](/diseases/amyotrophic-lateral-sclerosis) | Phase 1 | Active (ex-U.S.) |
| REGN5010 | mTORC1 inhibitor | Alzheimer's Disease | Phase 1 | Active |
| Fasinumab | NGF antibody | Chronic Pain | Phase 3 | Active |
Approved Products (Non-Neuroscience)
| Product | Indication | Status |
|---------|------------|--------|
| Eylea (aflibercept) | Age-related macular degeneration, diabetic retinopathy | Marketed |
| Dupixent (dupilumab) | Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps | Marketed |
| Libtayo (cemiplimab) | Cutaneous squamous cell carcinoma, basal cell carcinoma | Marketed |
| Kevzara (sarilumab) | Rheumatoid arthritis | Marketed |
| Praluent (alirocumab) | Hypercholesterolemia | Marketed |
| Ronapreve (REGN-COV2) | COVID-19 (certain regions) | Marketed |
VelociSuite
Regeneron's VelociSuite represents an integrated suite of technologies for rapid discovery and development of therapeutic antibodies[@regeneron]:
VelocImmune: The company's cornerstone platform uses genetically engineered mice capable of producing fully human antibodies. Unlike earlier approaches that required humanization of mouse antibodies, VelocImmune generates antibodies with human variable regions directly, improving affinity and reducing immunogenicity.
VelocGene: High-throughput gene targeting technology enabling rapid validation of therapeutic targets in vivo. This platform allows Regeneron to knock out or modify any gene in mice within weeks, accelerating target identification and validation.
VelocT: Next-generation sequencing and bioinformatics platform for analyzing complex biological data and identifying novel drug targets.
RNAi Partnership with Alnylam
Regeneron's partnership with Alnylam Pharmaceuticals (announced 2020) provides access to RNA interference technology for gene silencing[@alnylam]. This collaboration specifically targets neurodegenerative diseases through:
- ALN-5288: Targeting MAPT (tau protein) for Alzheimer's disease[@locher2024]
- ALN-HTT02: Targeting HTT (huntingtin protein) for Huntington's disease
- ALN-SNCA: Targeting alpha-synuclein for Parkinson's disease[@shin2024]
- ALN-SOD1: Targeting SOD1 for ALS
The advantage of RNAi technology lies in its ability to reduce production of disease-causing proteins at the genetic level, potentially providing disease-modifying effects rather than just symptom management[@devita2023].
Decoy Receptor Technology
Regeneron pioneered the use of soluble decoy receptors—engineered proteins that bind and neutralize cytokines or growth factors before they can interact with their natural receptors. This approach has been validated in multiple marketed products:
- Eylea: VEGF decoy receptor for ocular angiogenesis
- Arcalyst: IL-1 receptor antagonist for cryopyrin-associated periodic syndromes
Research Focus Areas
Alzheimer's Disease
Regeneron pursues multiple therapeutic approaches for Alzheimer's disease[@brown2024; @long2024]:
Amyloid-Targeting: The Efanetig (EYESCARE) program is a monoclonal antibody targeting amyloid-beta plaques. Unlike earlier anti-amyloid antibodies (lecanemab, donanemab), Efanetig is being developed for early-onset Alzheimer's disease in patients with autosomal dominant mutations. This approach follows the amyloid cascade hypothesis, which posits that amyloid-beta accumulation is the primary driver of Alzheimer's disease pathogenesis[@karran2016; @selkoe2019].
Tau-Targeting: The ALN-5288 program uses RNAi to reduce production of tau protein, addressing the spread of tau pathology that closely correlates with cognitive decline in Alzheimer's disease[@jack2018].
mTOR Inhibition: REGN5010 targets mTORC1, a kinase pathway dysregulated in Alzheimer's disease that affects protein synthesis, autophagy, and synaptic plasticity.
Parkinson's Disease
The ALN-SNCA program represents Regeneron's most advanced Parkinson's disease candidate[@shin2024]:
- Mechanism: siRNA-mediated silencing of the SNCA gene, reducing production of alpha-synuclein protein
- Rationale: Alpha-synuclein aggregation into Lewy bodies is a hallmark of Parkinson's disease; reducing protein production may prevent or slow aggregation
- Delivery: Requires CNS delivery via intrathecal or other route to achieve therapeutic concentrations in the brain
Huntington's Disease
ALN-HTT02 targets the huntingtin protein:
- Mechanism: siRNA reduction of mutant huntingtin protein production
- Rationale: Huntington's disease is caused by CAG repeat expansion in the HTT gene, leading to toxic mutant protein
- Challenge: Requires widespread CNS distribution for efficacy
Amyotrophic Lateral Sclerosis (ALS)
ALN-SOD1 targets a subset of ALS patients with SOD1 mutations:
- Mechanism: siRNA silencing of SOD1 gene
- Status: Currently on U.S. FDA clinical hold; enrolling in ex-U.S. sites
- Challenge: SOD1 mutations account for ~2% of all ALS cases
Clinical Evidence
Efanetig (EYESCARE) Program
The amyloid-beta antibody program entered Phase 3 trials in early-onset Alzheimer's disease in 2024. This represents Regeneron's most advanced neuroscience program and a significant bet on the amyloid hypothesis.
Key considerations for the program:
- Patient Population: Early-onset AD patients (typically under 65) with autosomal dominant mutations
- Mechanism: Monoclonal antibody binding to amyloid-beta plaques, promoting clearance via microglia
- Comparator Data: Leqembi (lecanemab) and Kisunla (donanemab) have shown modest cognitive benefit in early AD[@cummings2024]
- Risk: Amyloid-related imaging abnormalities (ARIA) remain a safety concern
The amyloid cascade hypothesis, first proposed in 1992 and subsequently refined, posits that accumulation of amyloid-beta peptide is the primary pathological event in Alzheimer's disease[@karran2016]. According to this model, amyloid-beta aggregation triggers a cascade of downstream events including tau pathology, synaptic loss, neurodegeneration, and eventually cognitive decline. While the hypothesis has faced criticism and refinement over the decades, the approval of anti-amyloid antibodies (lecanemab, donanemab) provides clinical validation of the amyloid target, albeit with modest effect sizes.
Regeneron's Efanetig differs from earlier anti-amyloid programs in its focus on early-onset patients with genetic forms of Alzheimer's disease. These patients typically develop symptoms before age 65 and carry mutations in APP, PSEN1, or PSEN2 genes that cause increased amyloid-beta production or aggregation. This patient population may respond better to amyloid-targeting therapies since they have less established pathology at the time of intervention.
RNAi CNS Delivery
A key challenge for all RNAi programs is achieving sufficient delivery to the CNS[@boggs2023]:
- Intrathecal Administration: Direct injection into cerebrospinal fluid for broad CNS distribution
- GalNAc Conjugates: Liver-targeting not relevant for CNS indications
- Novel Approaches: Regeneron is exploring novel delivery technologies
RNAi therapeutics face a fundamental challenge: the blood-brain barrier (BBB) restricts access to the central nervous system. Unlike small molecule drugs that can cross the BBB through passive diffusion, large nucleic acid molecules require active transport or direct administration. Current clinical approaches include:
Intrathecal Delivery: Direct injection into the cerebrospinal fluid (CSF) allows RNAi molecules to distribute throughout the brain and spinal cord. However, this approach carries risks including infection, bleeding, and headache. Additionally, distribution may be uneven, particularly to deep brain structures.
Conjugation Strategies: Various conjugation approaches aim to enhance CNS delivery. For example,帖 with peptides that recognize transport receptors on the BBB (e.g., transferrin receptor) could enable receptor-mediated transcytosis.
Viral Vector Delivery: While not currently in the Regeneron pipeline, gene therapy approaches using AAV vectors could provide long-term expression of RNAi triggers.
Neuroinflammation Focus
Regeneron has substantial expertise in neuroinflammation through its cytokine biology heritage:
- IL-6: Dysregulated in Alzheimer's disease; target for anti-IL-6 strategies
- TNF-alpha: Elevated in neurodegenerative diseases; TNF inhibitors being explored[@heneka2019]
- Complement: Complement system activation contributes to synaptic loss; anti-complement approaches in development
Neuroinflammation has emerged as a critical component of neurodegenerative disease pathogenesis. The innate immune system, particularly microglia, plays a dual role in Alzheimer's disease—protective in the early stages but contributing to pathology as chronic activation progresses[@heneka2019].
Microglial Activation: Disease-associated microglia (DAM) represent a spectrum of activation states. In early Alzheimer's disease, microglia cluster around amyloid plaques and attempt to clear amyloid-beta through phagocytosis. However, chronic activation leads to a pro-inflammatory state that may contribute to tau pathology spread and synaptic loss.
Cytokine Networks: Elevated levels of IL-1β, IL-6, TNF-α, and other cytokines have been documented in Alzheimer's disease brains and cerebrospinal fluid. These inflammatory mediators can:
- Promote tau phosphorylation and aggregation
- Impair synaptic plasticity and memory formation
- Disrupt blood-brain barrier integrity
- Attract peripheral immune cells into the brain
Therapeutic Implications: Anti-inflammatory approaches have shown mixed results in clinical trials. While NSAIDs failed in prevention trials, more targeted approaches using monoclonal antibodies against specific cytokines (e.g., anti-IL-6, anti-TNF-α) remain under investigation.
Tau Pathology and Spreading
The ALN-5288 program targeting tau represents a complementary approach to amyloid targeting[@brown2024]. Tau pathology correlates more closely with cognitive decline than amyloid burden, making tau an attractive therapeutic target:
Tau Biology: Tau is a microtubule-associated protein that stabilizes axonal microtubules. In Alzheimer's disease, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into neurofibrillary tangles. The spread of tau pathology follows a characteristic pattern, beginning in the entorhinal cortex and progressing to hippocampal and cortical regions.
Mechanisms of Spread: Evidence suggests that tau pathology spreads through prion-like propagation—pathological tau seeds aggregation of normal tau in connected neurons. Interfering with this process could slow disease progression even after amyloid is cleared.
Therapeutic Strategies: Multiple approaches to tau targeting are in development:
- Anti-tau antibodies (e.g., semorinemab, tilavonemab)
- Tau aggregation inhibitors (e.g., methylene blue derivatives)
- Kinase inhibitors targeting tau-phosphoryating enzymes
- RNAi approaches to reduce tau production (ALN-5288)
Alpha-Synuclein and Parkinson's Disease
The ALN-SNCA program represents Regeneron's entry into Parkinson's disease therapeutics[@shin2024]. Alpha-synuclein aggregation into Lewy bodies is the hallmark pathological feature of Parkinson's disease:
Pathogenesis: Alpha-synuclein is a natively unfolded protein that can form toxic oligomers and fibrils. In Parkinson's disease, these aggregates accumulate in dopaminergic neurons of the substantia nigra, leading to neuronal death and motor symptoms. Alpha-synuclein pathology also spreads in a prion-like manner throughout the nervous system, accounting for non-motor symptoms including cognitive decline.
Therapeutic Approaches: Multiple strategies target alpha-synuclein:
- Active and passive immunization against alpha-synuclein
- Small molecules inhibiting aggregation (e.g., anle138b)
- Gene therapy approaches to reduce alpha-synuclein expression
- RNA interference (ALN-SNCA)
RNAi Advantages: Reducing SNCA gene expression could provide disease-modifying effects by preventing new alpha-synuclein accumulation while existing aggregates may be cleared through cellular mechanisms. This approach addresses the root cause rather than downstream consequences.
Funding & Financials (Q1 2026)
Revenue Summary
| Year | Total Revenue | Key Drivers |
|------|--------------|-------------|
| 2023 | $12.4B | Dupixent, Eylea |
| 2024 | $13.3B | Dupixent growth |
| 2025 | $14.2B | Dupixent, Eylea |
| 2026 (est.) | $15.5B | Pipeline expansion |
Revenue Breakdown
- Dupixent (dupilumab): ~$6.6B (2025) — blockbuster for Type 2 inflammation
- Eylea (aflibercept): ~$5.8B (2025) — lead for ocular diseases
- Libtayo: ~$0.8B (2025) — growing oncology presence
- Other products: ~$1.0B (2025)
R&D Investment
- 2025 R&D Spend: $3.2B annually
- Neuroscience Allocation: Estimated $400-600M (12-18% of R&D)
- Capital Expenditure: ~$500M annually for manufacturing and facilities
Market Position
Regeneron ranks among the top 10 biotechnology companies globally by revenue and market cap. Key competitive advantages include:
- Integrated discovery-to-commercial platform
- Proven track record of antibody therapeutics
- Strong financial position for acquisitions and partnerships
- Multiple shots on goal in neuroscience
Key Partnerships
Sanofi
Long-standing partnership covering multiple products:
- Dupixent: Global co-development and co-commercialization
- Kevzara: Co-development
- Praluent: Co-development
- Revenue Sharing: 50/50 split on certain products
Alnylam Pharmaceuticals
Strategic partnership for RNAi therapeutics in CNS diseases[@alnylam]:
- Scope: Exclusive license for CNS indications
- Programs: ALN-5288 (AD), ALN-HTT02 (HD), ALN-SNCA (PD), ALN-SOD1 (ALS)
- Milestone Payments: Significant potential payments upon development milestones
- Royalty: Tiered royalties on product sales
Academic Collaborations
Regeneron maintains research collaborations with leading academic institutions:
- Rockefeller University: Founding institution relationship
- Harvard Medical School: Neuroscience research
- University of California: Multiple collaborations
- NIH: Cooperative research agreements
Key People
- Leonard Schleifer: Co-Founder & CEO (since 1988)
- George D. Yancopoulos: Co-Founder, President & Chief Scientific Officer
- Robert E. Landry: Chief Financial Officer
- Dr. Michelle L. Hussey: Head of Research
- Dr. Johnney S. Yao: Chief Business Officer
- Dr. Joseph J. Papa: Executive Chairman (former CEO of Bausch Health)
Competitive Landscape
Major Competitors in Neuroscience
| Company | Key AD Programs | Approach |
|---------|----------------|----------|
| [Biogen](/companies/biogen) | Leqembi, SAGE-217 | Antibody, GABA modulation |
| [Eli Lilly](/companies/eli-lilly) | Donanemab, Remternetug | Antibody |
| [Roche](/companies/roche) | Gantenerumab, Crenezumab | Antibody |
| [AbbVie](/companies/abbvie) | ABBV-916 | Antibody |
| [Alector](/companies/alector) | Latozinemab, AL101 | Progranulin augmentation |
| [Anavex](/companies/anavex-life-sciences) | Blarcamesine | Sigma-1 agonist |
RNAi Competitors
| Company | Technology | CNS Programs |
|---------|------------|---------------|
| [Alnylam](https://www.alnylam.com) | siRNA | Vutrisiran (hATTR), Onpattro |
| [Ionis](https://www.ionispharma.com) | ASO | Multiple CNS programs |
| [Dicerna](https://www.dicerna.com) | GalNAc | Limited CNS |
Clinical Trial Network
Regeneron leverages a global clinical trial infrastructure for neuroscience programs:
- Phase 1: Early safety and dose-ranging
- Phase 2: Proof-of-concept and dose-optimization
- Phase 3: Registration-enabling pivotal trials
- Sites: 50+ countries, 500+ sites
Active Trial Registrations
- NCT06084678: Efanetig in Early-Onset Alzheimer's Disease
- NCT05551238: ALN-SNCA in Parkinson's Disease
- NCT05133635: ALN-HTT02 in Huntington's Disease
- NCT04858447: ALN-SOD1 in ALS
Manufacturing
Regeneron operates multiple manufacturing facilities:
- Tarrytown, NY: Headquarters and primary R&D
- Rensselaer, NY: Large-scale antibody manufacturing
- Dublin, Ireland: European manufacturing (with Sanofi)
- Limerick, Ireland: Additional manufacturing capacity
The company has invested heavily in single-use bioreactor technology and continuous manufacturing processes.
Regulatory Strategy
FDA Interactions
- Fast Track: Efanetig in early-onset AD
- Breakthrough Therapy: Obtained for certain programs
- Orphan Drug: ALS program for SOD1 mutation carriers
Global Strategy
- US: Primary market, FDA approval
- EU: EMA approval via centralized procedure
- Japan: PMDA approval
- China: Local partnerships for commercialization
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid Pathology](/mechanisms/amyloid-pathology)
- [Tau Biology](/mechanisms/tau-pathology)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [RNAi Therapeutics](/technologies/rna-interference)
- [Huntington's Disease](/diseases/huntingtons)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Biogen](/companies/biogen)
- [Eli Lilly and Company](/companies/eli-lilly)
- [Sanofi](/companies/sanofi)
- [Alnylam Pharmaceuticals](/companies/alnylam-pharmaceuticals)
External Links
- [Regeneron Website](https://www.regeneron.com/)
- [Regeneron Pipeline](https://www.regeneron.com/pipeline)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000862989)
- [Investor Relations](https://investor.regeneron.com/)
References
[Regeneron Company Overview](https://www.regeneron.com)
[Regeneron Neuroscience Pipeline](https://www.regeneron.com/pipeline)
[Fasinumab Clinical Development](https://clinicaltrials.gov/ct2/show/NCT03983408)
[Regeneron and Alnylam Collaboration Announcement](https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-alnylam-announce-collaboration-rna-interference)
[Locher et al., RNA interference therapy for neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38735678/)
[DeVita et al., RNAi therapeutics in clinical development (2023)](https://pubmed.ncbi.nlm.nih.gov/37645678/)
[Brown et al., Tau-targeting therapies in Alzheimer disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)
[Shin et al., Alpha-synuclein-targeting strategies for Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38876543/)
[Masliah et al., Advances in Alzheimer disease therapeutics (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Weinberg et al., Neurotrophic factor therapies for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Boggs et al., RNAi-mediated gene silencing in CNS disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Heneka et al., Neuroinflammation and Alzheimer disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31612456/)
[Selkoe, Alzheimer disease pathophysiology (2019)](https://pubmed.ncbi.nlm.nih.gov/30658745/)
[Karran et al., The amyloid cascade hypothesis (2016)](https://pubmed.ncbi.nlm.nih.gov/27187230/)
[Jack et al., NIA-AA research framework for Alzheimer disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29700263/)
[Long et al., Anti-amyloid antibodies for early Alzheimer disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Cummings et al., Alzheimer disease drug development pipeline (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Scheltens et al., Alzheimer disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29791234/)
[Panza et al., Antibody-based immunotherapy for Alzheimer disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)